Home › Companies › Heron Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Heron Therapeutics, Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 11, 2026: 12 items on Heron Therapeutics, Inc.’s Form 8-K, filed June 16, 2026: 5 approved · 7 passed (calculated).
Meeting of October 13, 2025: 2 items on Heron Therapeutics, Inc.’s Form 8-K, filed October 15, 2025: 2 approved.
Notable dissent: 1 equity or compensation plan (15.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Rubric Capital (13D, 15.9%, as of October 17, 2025) · Clearline Capital (13F, 5.8%, as of September 30, 2026) · Tang Capital (13F, 4.7%, as of September 30, 2026)
Explore Heron Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Heron Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. Heron Therapeutics, Inc. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Mr. Collard | 87,289,779 | 4,336,869 | 185,208 | -- | 50,116,083 | 95% | Passed (calculated) | — |
| Elect Director: Mr. Cusack | 88,537,725 | 3,088,305 | 185,826 | -- | 50,116,083 | 97% | Passed (calculated) | — |
| Elect Director: Dr. Dissanaike | 87,960,023 | 3,729,614 | 122,219 | -- | 50,116,083 | 96% | Passed (calculated) | — |
| Elect Director: Mr. Johnson | 87,703,801 | 3,972,919 | 135,136 | -- | 50,116,083 | 96% | Passed (calculated) | — |
| Elect Director: Mr. Kaseta | 88,236,408 | 3,424,597 | 150,851 | -- | 50,116,083 | 96% | Passed (calculated) | — |
| Elect Director: Mr. Morgan | 88,295,437 | 3,381,282 | 135,137 | -- | 50,116,083 | 96% | Passed (calculated) | — |
| Elect Director: Mr. Waage | 85,276,872 | 6,399,195 | 135,789 | -- | 50,116,083 | 93% | Passed (calculated) | — |
| 2. The appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 139,715,514 | 1,706,193 | 506,232 | -- | 0 | 99% | Approved | — |
| 3. On a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2025 | 77,315,474 | 12,117,861 | 2,378,521 | -- | 50,116,083 | 86% | Approved | — |
| 4. The amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional 16,560,000 shares | 75,620,741 | 13,846,030 | 2,345,085 | -- | 50,116,083 | 85% | Approved | — |
| 5. The amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares | 83,765,950 | 6,496,205 | 1,549,701 | -- | 50,116,083 | 93% | Approved | — |
| 6. On a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan | 88,182,895 | 3,442,815 | 186,146 | -- | 50,116,083 | 96% | Approved | — |
Source: Heron Therapeutics, Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion, at the option of the holder, of convertible senior unsecured promissory notes due 2031 held by several non-affiliate | 89,632,206 | 5,575,457 | 218,161 | -- | 0 | 94% | Approved | — |
| 2. Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Series A Convertible Preferred Stock held by several non-affiliated holders, which could | 91,534,602 | 3,672,091 | 219,131 | -- | 0 | 96% | Approved | — |
Source: Heron Therapeutics, Inc., Form 8-K, filed with the SEC on October 15, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
142 asset managers disclosed a vote on at least one Heron Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held June 11, 2026.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 98.5% for (June 12, 2025 meeting) ▼ 2.2 pts
Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Adam Morgan
Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Morgan”): 88,295,437 for, 3,381,282 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 10,026,037 for, 238,090 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,843,515 | 5,512 | 1 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 599,122 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 304,486 | 216,960 | 0 | 0 | Mixed |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 164,898 | 0 | 0 | 0 | For |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| Global X | 73,839 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 0 | 15,618 | 0 | 0 | Against |
| T. Rowe Price | 13,942 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 12,671 | 0 | 0 | 0 | For |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 4,679 | 0 | 0 | 0 | For |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Meeting held June 11, 2026.
Combines 3 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Prior year: 94.4% for (June 12, 2025 meeting) ▼ 1.4 pts
Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Christian Waage
Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Waage”): 85,276,872 for, 6,399,195 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 8,380,271 for, 1,883,855 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,832,187 | 16,839 | 1 | 0 | For |
| Charles Schwab | 0 | 1,378,500 | 0 | 0 | Against |
| State Street | 599,122 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 304,486 | 216,960 | 0 | 0 | Mixed |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 0 | 164,898 | 0 | 0 | Against |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| Global X | 0 | 73,839 | 0 | 0 | Against |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 0 | 15,618 | 0 | 0 | Against |
| T. Rowe Price | 13,942 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 0 | 12,671 | 0 | 0 | Against |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 4,679 | 0 | 0 | 0 | For |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Meeting held June 11, 2026.
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Prior year: 98.5% for (June 12, 2025 meeting) ▼ 3.2 pts
Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Collard
Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Collard”): 87,289,779 for, 4,336,869 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 10,047,141 for, 216,984 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,849,001 | 24 | 1 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 599,122 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 304,486 | 216,960 | 0 | 0 | Mixed |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 164,898 | 0 | 0 | 0 | For |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| Global X | 73,839 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 15,618 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,942 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 12,671 | 0 | 0 | 0 | For |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 4,679 | 0 | 0 | 0 | For |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Meeting held June 11, 2026.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 97.3% for (June 12, 2025 meeting) ▼ 1.6 pts
Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Johnson
Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Johnson”): 87,703,801 for, 3,972,919 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 10,029,402 for, 234,724 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,832,199 | 16,827 | 1 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 599,122 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 304,486 | 216,960 | 0 | 0 | Mixed |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 164,898 | 0 | 0 | 0 | For |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| Global X | 73,839 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 15,618 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,942 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 12,671 | 0 | 0 | 0 | For |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 4,679 | 0 | 0 | 0 | For |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Meeting held June 11, 2026.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 97.4% for (June 12, 2025 meeting) ▼ 1.1 pts
Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Michael Kaseta
Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Kaseta”): 88,236,408 for, 3,424,597 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 10,047,148 for, 216,978 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,849,008 | 18 | 1 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 599,122 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 304,486 | 216,960 | 0 | 0 | Mixed |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 164,898 | 0 | 0 | 0 | For |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| Global X | 73,839 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 15,618 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,942 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 12,671 | 0 | 0 | 0 | For |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 4,679 | 0 | 0 | 0 | For |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Meeting held June 11, 2026.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Prior year: 96.9% for (June 12, 2025 meeting) ▼ 0.9 pts
Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Sharmila Dissanaike, M.D., FACS, FCCM
Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Dissanaike”): 87,960,023 for, 3,729,614 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 10,232,767 for, 31,360 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,837,694 | 11,333 | 0 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 599,122 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 521,446 | 0 | 0 | 0 | For |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 164,898 | 0 | 0 | 0 | For |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| Global X | 73,839 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 0 | 15,618 | 0 | 0 | Against |
| T. Rowe Price | 13,942 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 12,671 | 0 | 0 | 0 | For |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 4,679 | 0 | 0 | 0 | For |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Meeting held June 11, 2026.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Tom Cusack
Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Cusack”): 88,537,725 for, 3,088,305 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 10,047,148 for, 216,978 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,849,008 | 18 | 1 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 599,122 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 304,486 | 216,960 | 0 | 0 | Mixed |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 164,898 | 0 | 0 | 0 | For |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| Global X | 73,839 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 15,618 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,942 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 12,671 | 0 | 0 | 0 | For |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 4,679 | 0 | 0 | 0 | For |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Meeting held October 13, 2025.
Combines 2 wordings of this item as funds reported it.
94% Approved · of votes cast
Description as filed by funds: TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THE CONVERSION OF CONVERTIBLE SENIOR UNSECURED PROMISSORY NOTES DUE 2031 HELD BY SEVERAL NON-AFFILIATED PURCHASERS, WHICH COULD, UNDER CERTAIN CIRCUMSTANCES THAT MAY OCCUR IN THE FUTURE, EXCEED 19.99% OF THE NUMBER OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING PRIOR TO SUCH ISSUANCE.
Heron Therapeutics, Inc.’s own tally for this item (“1. Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion, at the option of the holder, of convertible senior unsecured promissory note”): 89,632,206 for, 5,575,457 against — passed, per its Form 8-K filed October 15, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The votes with respect to each of the two proposals voted on at the Special Meeting are set forth below: Proposal 1: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion, at t…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 38 asset managers below reported 11,738,277 for, 134,717 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,134,000 | 0 | 0 | 0 | For |
| BlackRock | 1,933,129 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,324,908 | 0 | 0 | 0 | For |
| Charles Schwab | 759,955 | 0 | 0 | 0 | For |
| State Street | 652,774 | 7,846 | 0 | 0 | For |
| TIAA | 323,440 | 0 | 0 | 0 | For |
| Goldman Sachs | 275,907 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| SEI | 141,815 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 118,392 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 103,657 | 0 | 0 | 0 | For |
| Fidelity | 90,597 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 79,593 | 0 | 0 | 0 | For |
| Equitable | 79,023 | 0 | 0 | 0 | For |
| John Hancock | 78,683 | 0 | 0 | 0 | For |
| Global X | 75,637 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 69,478 | 0 | 0 | 0 | For |
| Pacific Life | 67,920 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 62,600 | 0 | 0 | 0 | For |
| Brighthouse | 56,019 | 0 | 0 | 0 | For |
| Voya | 36,633 | 0 | 0 | 0 | For |
| ProShares | 34,403 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 32,941 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,992 | 0 | 0 | 0 | For |
| Calvert | 15,618 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).
Meeting held October 13, 2025.
Combines 2 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THE CONVERSION OF THE COMPANY'S SERIES A CONVERTIBLE PREFERRED STOCK HELD BY SEVERAL NON-AFFILIATED HOLDERS, WHICH COULD, UNDER CERTAIN CIRCUMSTANCES THAT MAY OCCUR IN THE FUTURE, EXCEED 19.99% OF THE NUMBER OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING PRIOR TO SUCH ISSUANCE.
Heron Therapeutics, Inc.’s own tally for this item (“2. Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Series A Convertible Preferred Stock held by sever”): 91,534,602 for, 3,672,091 against — passed, per its Form 8-K filed October 15, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Series A Convertible Preferred Stock held by several non-affiliated holders, which …”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 38 asset managers below reported 11,872,994 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,134,000 | 0 | 0 | 0 | For |
| BlackRock | 1,933,129 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,324,908 | 0 | 0 | 0 | For |
| Charles Schwab | 759,955 | 0 | 0 | 0 | For |
| State Street | 660,620 | 0 | 0 | 0 | For |
| TIAA | 323,440 | 0 | 0 | 0 | For |
| Goldman Sachs | 275,907 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| SEI | 141,815 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 103,657 | 0 | 0 | 0 | For |
| Fidelity | 90,597 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 79,593 | 0 | 0 | 0 | For |
| Equitable | 79,023 | 0 | 0 | 0 | For |
| John Hancock | 78,683 | 0 | 0 | 0 | For |
| Global X | 75,637 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 69,478 | 0 | 0 | 0 | For |
| Pacific Life | 67,920 | 0 | 0 | 0 | For |
| PACE SELECT ADVISORS TRUST | 62,600 | 0 | 0 | 0 | For |
| Brighthouse | 56,019 | 0 | 0 | 0 | For |
| Voya | 36,633 | 0 | 0 | 0 | For |
| ProShares | 34,403 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 32,941 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 22,992 | 0 | 0 | 0 | For |
| Calvert | 15,618 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).
Meeting held June 11, 2026.
Combines 2 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: TO AMEND THE COMPANY'S 1997 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY AN ADDITIONAL 10,000,000 SHARES.
Heron Therapeutics, Inc.’s own tally for this item (“5. The amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares”): 83,765,950 for, 6,496,205 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 5: The Company's stockholders approved the amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 10,047,117 for, 217,000 against, 10 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,848,977 | 40 | 10 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 599,122 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 304,486 | 216,960 | 0 | 0 | Mixed |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 164,898 | 0 | 0 | 0 | For |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| Global X | 73,839 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 15,618 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,942 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 12,671 | 0 | 0 | 0 | For |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 4,679 | 0 | 0 | 0 | For |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Meeting held June 11, 2026.
Combines 2 wordings of this item as funds reported it.
85% Approved · of votes cast
Description as filed by funds: TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2007 AMENDED AND RESTATED EQUITY INCENTIVE PLAN, TO, AMONG OTHER THINGS, INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY AN ADDITIONAL 16,560,000 SHARES.
Heron Therapeutics, Inc.’s own tally for this item (“4. The amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional”): 75,620,741 for, 13,846,030 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 4: The Company's stockholders approved the amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional 16,560,000 shares:”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 9,029,248 for, 1,234,863 against, 16 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,837,633 | 11,378 | 16 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 0 | 599,122 | 0 | 0 | Against |
| Jacob Funds Inc. | 304,486 | 216,960 | 0 | 0 | Mixed |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,638 | 1 | 0 | 0 | For |
| Equitable | 75,213 | 121,070 | 0 | 0 | Mixed |
| SEI | 164,898 | 0 | 0 | 0 | For |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 118,392 | 0 | 0 | Against |
| Global X | 73,839 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 0 | 44,140 | 0 | 0 | Against |
| Victory Capital | 0 | 21,233 | 0 | 0 | Against |
| ProShares | 0 | 19,299 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 17,391 | 0 | 0 | Against |
| Calvert | 0 | 15,618 | 0 | 0 | Against |
| T. Rowe Price | 0 | 13,942 | 0 | 0 | Against |
| Venerable Variable Insurance Trust | 12,671 | 0 | 0 | 0 | For |
| Principal | 0 | 6,978 | 0 | 0 | Against |
| Brinker Capital Destinations Trust | 0 | 4,679 | 0 | 0 | Against |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 0 | 4,190 | 0 | 0 | Against |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Meeting held June 11, 2026.
Combines 2 wordings of this item as funds reported it.
96% Approved · of votes cast
Description as filed by funds: TO RATIFY, ON A NONBINDING ADVISORY BASIS, THE ADOPTION OF THE TAX BENEFITS PRESERVATION PLAN.
Heron Therapeutics, Inc.’s own tally for this item (“6. On a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan”): 88,182,895 for, 3,442,815 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 6: The Company's stockholders ratified, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 9,900,066 for, 364,060 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,849,007 | 19 | 1 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 592,854 | 6,268 | 0 | 0 | For |
| Jacob Funds Inc. | 304,486 | 216,960 | 0 | 0 | Mixed |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 164,898 | 0 | 0 | 0 | For |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 118,392 | 0 | 0 | Against |
| Global X | 73,839 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 15,618 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 13,942 | 0 | 0 | Against |
| Venerable Variable Insurance Trust | 12,671 | 0 | 0 | 0 | For |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 0 | 4,679 | 0 | 0 | Against |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Meeting held June 11, 2026.
Combines 7 wordings of this item as funds reported it.
86% Approved · of votes cast
Prior year: 95.7% for (June 12, 2025 meeting) ▼ 9.3 pts
Description as filed by funds: TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCAL YEAR ENDED DECEMBER 31, 2025.
Heron Therapeutics, Inc.’s own tally for this item (“3. On a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2025”): 77,315,474 for, 12,117,861 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: The Company's stockholders approved, on a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2025:”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,843,443 | 5,570 | 16 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 599,122 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 304,486 | 216,960 | 0 | 0 | Mixed |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 0 | 232,800 | 0 | 0 | Against |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 0 | 164,898 | 0 | 0 | Against |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| Global X | 0 | 73,839 | 0 | 0 | Against |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 15,618 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,942 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 0 | 12,671 | 0 | 0 | Against |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 4,679 | 0 | 0 | 0 | For |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Fund voting reports, all 36 managers: 9,557,334 for, 706,779 against, 16 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 26,713,503 | 0 | 0 | 0 | For |
| Clearline Capital LP | 11,586,116 | 0 | 0 | 0 | For |
| Velan Capital Investment Management LP | 10,519,836 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 0 | 6,127,998 | 0 | 0 | Against |
| PALISADE CAPITAL MANAGEMENT, LP | 2,391,618 | 0 | 0 | 0 | For |
| BlackRock | 1,795,041 | 4,424 | 0 | 0 | For |
| State Street | 1,413,667 | 11,064 | 0 | 0 | For |
| Stonepine Capital Management, LLC | 1,402,191 | 0 | 0 | 0 | For |
| Charles Schwab | 1,379,048 | 0 | 0 | 0 | For |
| Northern Trust | 605,710 | 4,681 | 0 | 0 | For |
| Orchard Capital Management, LLC | 0 | 458,766 | 0 | 0 | Against |
| AQR | 414,902 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 377,347 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 358,920 | 0 | 0 | 0 | For |
| Renaissance | 251,892 | 0 | 0 | 0 | For |
| DE Shaw | 246,404 | 0 | 0 | 0 | For |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 0 | 243,570 | 0 | 0 | Against |
| NexPoint Advisors, L.P. | 0 | 242,950 | 0 | 0 | Against |
| Goldman Sachs | 215,260 | 0 | 0 | 0 | For |
| AllianceBernstein | 198,550 | 0 | 0 | 0 | For |
| Vanguard | 170,674 | 0 | 0 | 0 | For |
| SEI | 0 | 165,009 | 0 | 0 | Against |
| PNC BANK, NATIONAL ASSOCIATION | 0 | 81,818 | 0 | 0 | Against |
| NEW YORK STATE COMMON RETIREMENT FUND | 0 | 76,616 | 0 | 0 | Against |
| STIFEL NICOLAUS & CO INC \MO\ | 75,062 | 0 | 0 | 0 | For |
Institutional-manager reports, all 113 managers: 60,802,334 for, 7,593,382 against. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held June 11, 2026.
99% Approved · of votes cast
Prior year: 99.1% for (June 12, 2025 meeting) ▼ 0.3 pts
Description as filed by funds: TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Heron Therapeutics, Inc.’s own tally for this item (“2. The appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 139,715,514 for, 1,706,193 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: The Company's stockholders ratified the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 10,258,627 for, 5,500 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 5,843,527 | 5,500 | 1 | 0 | For |
| Charles Schwab | 1,378,500 | 0 | 0 | 0 | For |
| State Street | 599,122 | 0 | 0 | 0 | For |
| Jacob Funds Inc. | 521,446 | 0 | 0 | 0 | For |
| Goldman Sachs | 473,272 | 0 | 0 | 0 | For |
| HIGHLAND GLOBAL ALLOCATION FUND | 232,800 | 0 | 0 | 0 | For |
| Fidelity | 197,639 | 0 | 0 | 0 | For |
| Equitable | 196,283 | 0 | 0 | 0 | For |
| SEI | 164,898 | 0 | 0 | 0 | For |
| BlackRock | 143,606 | 0 | 0 | 0 | For |
| Lincoln Financial | 118,392 | 0 | 0 | 0 | For |
| Global X | 73,839 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 68,575 | 0 | 0 | 0 | For |
| Pacific Life | 57,569 | 0 | 0 | 0 | For |
| Invesco | 44,140 | 0 | 0 | 0 | For |
| Victory Capital | 21,233 | 0 | 0 | 0 | For |
| ProShares | 19,299 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 17,391 | 0 | 0 | 0 | For |
| Calvert | 15,618 | 0 | 0 | 0 | For |
| T. Rowe Price | 13,942 | 0 | 0 | 0 | For |
| Venerable Variable Insurance Trust | 12,671 | 0 | 0 | 0 | For |
| Principal | 6,978 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 4,679 | 0 | 0 | 0 | For |
| Nationwide | 4,470 | 0 | 0 | 0 | For |
| Morgan Stanley | 4,190 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 189,279,369 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.71% |
| 2 | BlackRock | 1.02% |
| 3 | T. Rowe Price | 0.70% |
| 4 | Charles Schwab | 0.40% |
| 5 | State Street | 0.35% |
| 6 | TIAA | 0.17% |
| 7 | Goldman Sachs | 0.15% |
| 8 | HIGHLAND GLOBAL ALLOCATION FUND | 0.12% |
| 9 | SEI | 0.07% |
| 10 | Lincoln Financial | 0.06% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Rubric Capital Management LP | 14.11% |
| 2 | Clearline Capital LP | 6.12% |
| 3 | Velan Capital Investment Management LP | 5.56% |
| 4 | ORBIMED ADVISORS LLC | 3.24% |
| 5 | PALISADE CAPITAL MANAGEMENT, LP | 1.26% |
| 6 | BlackRock | 0.95% |
| 7 | State Street | 0.75% |
| 8 | Stonepine Capital Management, LLC | 0.74% |
| 9 | Charles Schwab | 0.73% |
| 10 | Northern Trust | 0.32% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Rubric Capital Management LP | 30,046,828 | 15.87% | Proxy statement (DEF 14A), proxy filed April 30, 2026 |
| Clearline Capital, L.P. | 12,235,239 | 6.46% | Proxy statement (DEF 14A), proxy filed April 30, 2026 |
| Current Executive Officers and Directors as a group (10 persons) | 11,586,424 | 6.12% | Proxy statement (DEF 14A), proxy filed April 30, 2026 |
| BlackRock | 10,106,422 | 5.34% | Form 13F, quarter ended March 31, 2026 |
| Subsidiaries or business divisions of Vanguard Group Inc. | 9,820,384 | 5.19% | Proxy statement (DEF 14A), proxy filed April 30, 2026 |
| Vanguard Group | 9,820,384 | 5.19% | Form 13F, quarter ended March 31, 2026 |
| Adam Morgan | 9,443,929 | 4.99% | Proxy statement (DEF 14A), proxy filed April 30, 2026 |
| Millennium Management | 7,630,527 | 4.03% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 4,010,087 | 2.12% | Form 13F, quarter ended March 31, 2026 |
| State Street | 3,843,672 | 2.03% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 189,279,369 shares outstanding, as reported by Heron Therapeutics, Inc. on its Form 10-Q dated May 6, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Heron Therapeutics, Inc.'s 2 shareholder meetings in the 2025-2026 proxy season (held October 13, 2025 and June 11, 2026), 142 asset managers reported votes on at least one of its 14 ballot items in their SEC Form N-PX filings, covering 1,780 separate fund positions. On the most widely held item of the season, voted at the meeting held June 11, 2026 — TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS… — Heron Therapeutics, Inc.'s filing reports the proposal as approved, with 86% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Heron Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Heron Therapeutics, Inc.’s 10-Q dated May 6, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Heron Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Heron Therapeutics (HRTX) 2025-2026 Annual & Special Meetings”, https://proxyvotesnow.com/company/heron-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.